このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

精神医学の喫煙削減に関する介入研究 (TABAPSY)

2026年10月7日 更新者:GCS-CCOMS

外来精神医学で治療されたメンタルヘルスユーザーの喫煙を減らすための介入の評価

The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 25 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers. However, tobacco reduction actions specifically targeting these people remain insufficiently developed, particularly in psychiatry where this addiction is often banalized and its treatment neglected.

The objective of this study is to evaluate an intervention ('Tabapsy') co-constructed with mental health services users, mental health professionals, and general practitioners and targeting adult patients followed in ambulatory psychiatry. The main objective is to evaluate the effectiveness of the intervention on short-term smoking cessation (cessation for at least 7 days) among regular smokers at 3 months. Secondary objectives include evaluation of its cost-effectiveness and implementation. To this end, a national cluster-randomized controlled study will be carried out, supplemented by qualitative interviews to study the implementation of the intervention.

調査の概要

状態

募集

詳細な説明

The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 20 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers.

While studies found that people under psychiatric care are as motivated as others to stop smoking, the literature also shows that psychiatric care systems tolerate, underestimate and even encourage smoking among users, despite the fact that psychiatric care, whether at hospital or in an ambulatory setting, is conducive to changes in smoking behaviour and to the implementation of a smoking cessation approach, notably because of anti-smoking regulations in hospitals. In addition, withdrawal symptoms is stronger in this population and smoking cessation would therefore need to be adapted.

Against this backdrop, a smoking cessation intervention ('Tabapsy') was co-constructed with the various stakeholders (users with mental disorders, mental health professionals and general practitioners). Its aim is to encourage and support smoking cessation among people with mental disorders followed in ambulatory psychiatry by medical psychological centers (CMP). It consists of two parts: a campaign to promote smoking cessation within the CMP, and the setting up of an intervention to help people stop smoking. The latter comprises of:

  1. A general information meeting, to encourage motivation to start smoking cessation;
  2. An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained;
  3. Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations;
  4. Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking.

The intervention also relies on a facilitator specifically recruited to set up the intervention and run the various workshops in the CMP. It is complemented by a website that will contain all the resources and information presented during the meetings/workshops.

The primary objective of the study is to evaluate the effectiveness of the "Tabapsy" intervention on short-term smoking cessation (cessation for at least 7 days) at 3 months among regular smokers followed by adult psychiatric CMPs. Secondary objectives include assessing its cost-effectiveness and implementation.

A cluster-randomized controlled trial will be carried out to evaluate the intervention. The cluster is the "psychiatric sector", i.e., the public care entity responsible for organizing the mental health care of a population within a pre-specified geographical area (including hospital and ambulatory care) in France. A psychiatric sector may include one or multiple CMPs depending on the size of the population it serves. Psychiatric sectors will be randomized into one of two groups (intervention or usual practice).

It will be supplemented by a qualitative study to study the implementation of the intervention.

All regular smokers (at least one cigarette a day) who agree to participate will be asked to complete questionnaires on a WebApp at inclusion, and again at 3 and 6 months. Additional questionnaires will be available in the intervention group. Questions will focus on user characteristics, tobacco consumption, level of nicotine dependence, motivation to quit, use of cessation aids, level of mental and physical well-being, smoking-related knowledge and representations, and in the intervention group, participation in the intervention and satisfaction.

6,250 participants will be included over 12 months, in 22 participating sectors.

研究の種類

介入

入学 (推定)

6500

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Saint-Claude、グアドループ、97122
        • 募集
        • Public mental health establishment of Guadeloupe (96G06)
        • コンタクト:
        • 主任研究者:
          • Isabelle DELAROZIERE, MD
      • Saint-Claude、グアドループ、97122
        • 募集
        • Public mental health establishment of Guadeloupe (96G01)
        • コンタクト:
        • 主任研究者:
          • Magloire MPEMBI, MD
      • Armentières、フランス、59280
        • 完了
        • Public mental health establishment of Lille Metropole (59G16-G17)
      • Armentières、フランス、59280
        • 完了
        • Public mental health establishment of Lille Metropole (59G21)
      • Bailleul、フランス、59270
        • 完了
        • Flanders public mental health establishment (59G05/06)
      • Laxou、フランス、54520
        • 完了
        • Psychotherapeutic center of Nancy (54G02-06)
      • Lille、フランス、59000
        • 引きこもった
        • University Hospital Center of Lille (59G08)
      • Nanterre、フランス、92014
        • 完了
        • Hospital Care Center of Nanterre (92G10)
      • Paris、フランス、75014
        • 完了
        • University Hospital Group Paris Neurosciences & Psychiatry (75G04)
      • Rouffach、フランス、68250
        • 完了
        • Hospital Center of Rouffach (68G02/03)
      • Rouffach、フランス、68250
        • 完了
        • Hospital Center of Rouffach (68G08/09)
      • Rouffach、フランス、68250
        • 完了
        • Hospital Center of Rouffach (Pôle LTD - 68G04/05)
      • Saint-Maurice、フランス、94410
        • 完了
        • Hospitals of Paris Est Val de Marne (94G01)
      • Saint-Maurice、フランス、94410
        • 完了
        • Hospitals of Paris Est Val de Marne (94G16)
      • Saint-Maurice、フランス、94410
        • 完了
        • Hospitals of Paris Est Val de Marne (Paris 11)
      • Saint-Maurice、フランス、94410
        • 完了
        • Hospitals of Paris Est Val de Marne (Paris 12)
      • Saint-Maurice、フランス、94410
        • 完了
        • Hospitals of Paris Est Val de Marne (Paris Centre)
      • Saint-Venant、フランス、62350
        • 完了
        • Public mental health establishment of Val de Lys Artois (62G09)
      • Saint-Venant、フランス、62350
        • 完了
        • Public mental health establishment of Val de Lys Artois (62G12)
      • Saint-Venant、フランス、62350
        • 完了
        • Public mental health establishment of Val de Lys Artois (Pôle du Ternois)
      • Étampes、フランス、91150
        • 募集
        • Barthelemy Durand public health establishment (91G05)
        • コンタクト:
        • 主任研究者:
          • Amina AMRANDI, MD
      • Saint-Paul、再会、97460
        • 完了
        • Public mental health establishment of Reunion Island (Pôle Nord)

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Regular smokers (at least one cigarette per day)
  • Followed in psychiatric ambulatory care at one of the participating sectors' CMPs
  • Adults (18 years or older)
  • Covered by the statuary health insurance
  • Who gave their informed consent to participate to the study

Exclusion Criteria:

  • Users under guardianship or legal protection,
  • Psychological state incompatible with completing the questionnaire,
  • Persons with no command or understanding of the French language

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Intervention arm

Sectors randomized to the intervention group will implement the 'Tabapsy' intervention.

The Tabapsy intervention consists in a campaign to promote smoking cessation within the CMP, and an intervention to help people stop smoking which comprises of a) A general information meeting; b) An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained; c) Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations; d) Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking.

The intervention relies on a facilitator specifically recruited to implement and run the intervention in the CMP. It is complemented by a website that will contain all the resources and information presented dur

他の:Usual care

Sectors randomized to the control group will continue implementing their usual smoking cessation promotion.

Usual care corresponds to usual practices regarding smoking cessation activities in participating sectors. Those practices may vary (enquiring whether a patient is a smoker or not, offering smoking cessation if they are or only if the patient asks, etc.)

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Short-term smoking cessation
時間枠:3 months

Short-term smoking cessation corresponds to a smoking cessation of at least 7 days, assessed among regular smoker (at least one cigarette a day) included in the study.

3 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Motivation to stop smoking
時間枠:3 and 6 months

The motivation to stop smoking will be assessed using the Q-Mat ("Questionnaire de motivation à l'arrêt du tabac") scale. The computed score ranges from 0 to 20, 20 representing the highest motivation.

3 and 6 months
Voluntary quit attempts lasting at least 24 hours in the last 3 months
時間枠:3 and 6 months

Number of voluntary quit attempts assessed both as percentage of users reporting at least one quit attempt and mean number of quit attempts per use

3 and 6 months
Voluntary quit attempts lasting at least 7 days in the last 3 months
時間枠:3 and 6 months

Number of voluntary quit attempts assessed both as percentage of users reporting at least one quit attempt and mean number of quit attempts per user.

3 and 6 months
Tobacco consumption
時間枠:3 and 6 months

Number of cigarettes smoked per day

3 and 6 months
Nicotine dependence
時間枠:3 and 6 months

Nicotine dependence will be measured by the 6-question Fagerström test.

3 and 6 months
Short-term smoking cessation
時間枠:6 months

Short-term smoking cessation corresponds to a smoking cessation of at least 7 days, assessed among regular smoker (at least one cigarette a day) included in the study.

6 months
Medium-term smoking cessation
時間枠:At 3 and 6 months

Medium-term smoking cessation corresponds to a smoking cessation of at least 30 days, assessed among regular smoker (at least one cigarette a day) included in the study.

At 3 and 6 months
Use of smoking cessation aids
時間枠:3 and 6 months

Number of participants using smoking cessation aids (nicotine replacement therapy and other smoking cessation medications (varenicline or bupropion), electronic cigarettes, and health professionals, assessed together and separately

3 and 6 months
Level of mental well-being
時間枠:3 and 6 months

Level of mental well-being assessed with a visual analog scale ranging from 1 to 10, 10 representing the highest level of mental well-being

3 and 6 months
Level of physical well-being
時間枠:3 and 6 months

Level of physical well-being assessed with a visual analog scale ranging from 1 to 10, 10 representing the highest level of physical well-being

3 and 6 months
Knowledge and representations surrounding tobacco use
時間枠:3 and 6 months

Knowledge and representations surrounding tobacco use will be assessed using a dedicated questionnaire addressed to all the included population as well as to patients who participated to a given workshop

3 and 6 months
Cost-effectiveness (short-term)
時間枠:A 6 months

Incremental cost-effectiveness ratio in cost per additional weaning of at least 7 days.

A 6 months
Cost-effectiveness (long-term)
時間枠:6 months

Incremental cost-effectiveness ratio in cost per life-year gained over the entire life of users, using extrapolated data and economic modeling (Markov model) to assess lifetime costs and effectiveness 'till all patients in the model are deceased.

6 months
Budgetary impact (costs)
時間枠:5 years after hypothetical generalization

Direct costs will be calculated with and without the Tabapsy intervention to assess the budgetary impact of its generalization.

5 years after hypothetical generalization
Budgetary impact (health benefits)
時間枠:5 years after hypothetical generalization

The number of users who have stopped smoking for at least 7 days will be calculated with and without the Tabapsy intervention to assess the health gains associated with its generalization.

5 years after hypothetical generalization
Implementation
時間枠:6 months

The implementation of the intervention and its components will be assessed using qualitative methods through semi-structured interviews conducted with 25 mental health users et 25 mental health professionnals of the intervention group).

6 months
Satisfaction level
時間枠:3 and 6 months

Users who participated in one of the components of the intervention will be asked to rate their satisfaction using a visual analog scale ranging from 0 to 10, with 10 corresponding to the highest satisfaction.

3 and 6 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Jean-Luc ROELANDT, MD、GCS-CCOMS & INSERM ECEVE 1123
  • スタディディレクター:Karine CHEVREUL, MD and Pr of public health、Evaluation and research in health services and policies for vulnerable populations, French National Institute for Health and Medical Research (INSERM ECEVE 11 23)

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年1月15日

一次修了 (実際)

2026年7月15日

研究の完了 (推定)

2026年11月14日

試験登録日

最初に提出

2025年2月18日

QC基準を満たした最初の提出物

2025年4月7日

最初の投稿 (実際)

2025年4月13日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月8日

QC基準を満たした最後の更新が送信されました

2026年10月7日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • 2024-A01474-43
  • A19017HS (その他の識別子:Institute for Public Health Research (IRESP))

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する